Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and UnitedHealth Group. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$698.89 -2.34 (-0.33%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$699.00 +0.11 (+0.02%)
As of 05:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The current stock price is around $685, which reflects a significant market presence and potential for growth.
  • Analysts have a strong consensus on the stock, with a majority rating it as a "buy," indicating confidence in its future performance.
  • Recent insider buying activity suggests that executives believe in the company's prospects, with notable purchases made by key executives.

Cons of Eli Lilly and Company

  • Recent downgrades from analysts, including a shift from "strong-buy" to "moderate sell," may indicate concerns about future performance.
  • The stock has experienced fluctuations, with a one-year high of $972.53 and a low of $623.78, suggesting volatility that could deter risk-averse investors.
  • Insider ownership is relatively low at 0.13%, which may raise questions about the alignment of interests between management and shareholders.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$663.68 billion
P/E Ratio
45.68
Consensus Rating
Moderate Buy
Consensus Price Target
$950.17 (+36.0% Upside)
Volume
4.99 million shares
Average Volume
6.59 million shares
Today's Range
$693.50
$707.75
50-Day Range
$625.15
$818.56
52-Week Range
$623.78
$972.53
Dividend Yield
0.86%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$176.26 -0.38 (-0.22%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$176.38 +0.12 (+0.07%)
As of 05:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price is around $174.96, reflecting a stable market position and potential for growth.
  • Johnson & Johnson reported strong earnings, with earnings per share (EPS) of $2.77, exceeding analysts' expectations, indicating robust financial health.
  • The company has a solid revenue stream, with a reported revenue of $23.74 billion, showcasing its ability to generate significant income.

Cons of Johnson & Johnson

  • Recent downgrades from analysts, such as Leerink Partners reducing their rating to "market perform," may indicate concerns about future performance.
  • The company experienced a slight decline in EPS compared to the previous year, which could signal potential challenges in maintaining growth.
  • With a P/E ratio of 18.71, the stock may be considered overvalued compared to industry peers, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$425.41 billion
P/E Ratio
18.85
Consensus Rating
Moderate Buy
Consensus Price Target
$174.50 (-1.0% Downside)
Volume
9.28 million shares
Average Volume
8.41 million shares
Today's Range
$176.10
$177.57
50-Day Range
$149.81
$176.76
52-Week Range
$140.68
$177.57
Dividend Yield
2.94%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$206.23 -0.46 (-0.22%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$207.08 +0.85 (+0.41%)
As of 04:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • The current stock price is around $204.78, reflecting a recent increase, which may indicate positive market sentiment towards AbbVie.
  • AbbVie has received multiple upgrades from analysts, including a "strong-buy" rating from Daiwa America, suggesting strong confidence in the company's future performance.
  • The company has a solid market capitalization of approximately $361.75 billion, indicating its substantial size and stability in the market.

Cons of AbbVie

  • The company has a high price-to-earnings (P/E) ratio of 97.51, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • AbbVie has a significant debt-to-equity ratio of 44.14, suggesting that the company relies heavily on debt financing, which could pose risks in a rising interest rate environment.
  • Insider ownership is relatively low at 0.25%, which may indicate a lack of alignment between management and shareholder interests.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$365.13 billion
P/E Ratio
98.21
Consensus Rating
Moderate Buy
Consensus Price Target
$214.95 (+4.2% Upside)
Volume
6.08 million shares
Average Volume
4.89 million shares
Today's Range
$205.96
$208.34
50-Day Range
$181.89
$206.65
52-Week Range
$163.81
$218.66
Dividend Yield
3.17%
UnitedHealth Group stock logo

4. UnitedHealth Group NYSE:UNH

$308.84 +4.83 (+1.59%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$309.88 +1.04 (+0.34%)
As of 05:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The current stock price is around $309.77, reflecting a significant trading volume, which indicates strong investor interest and liquidity.
  • UnitedHealth Group reported a revenue increase of 12.9% year-over-year, showcasing robust growth in its business operations.
  • The company has a solid return on equity of 23.32%, indicating effective management and profitability relative to shareholder equity.

Cons of UnitedHealth Group

  • The company recently missed earnings expectations, reporting $4.08 EPS compared to the consensus estimate of $4.45, which may raise concerns about its short-term performance.
  • UnitedHealth Group's stock has experienced significant volatility, with a 1-year high of $630.73 and a low of $234.60, indicating potential risks for investors.
  • The debt-to-equity ratio stands at 0.73, which, while manageable, suggests that the company is utilizing a moderate level of debt that could impact financial stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$275.33 billion
P/E Ratio
13.38
Consensus Rating
Moderate Buy
Consensus Price Target
$367.71 (+19.1% Upside)
Volume
39.48 million shares
Average Volume
21.95 million shares
Today's Range
$307.42
$316.40
50-Day Range
$237.40
$325.83
52-Week Range
$234.60
$630.73
Dividend Yield
2.91%
Novartis stock logo

5. Novartis NYSE:NVS

$123.96 -0.25 (-0.20%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$124.79 +0.83 (+0.67%)
As of 05:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The current stock price is around $124, reflecting a strong performance in the market.
  • Recent upgrades from analysts, including a shift from "underweight" to "equal weight" by Morgan Stanley, indicate positive sentiment towards the stock.
  • Novartis AG has demonstrated solid financial health with a return on equity of over 41%, suggesting effective management and profitability.

Cons of Novartis

  • Despite recent upgrades, there are still two analysts who have rated the stock with a sell rating, suggesting some skepticism about its future performance.
  • The stock has experienced fluctuations, with a twelve-month low of $96.06, indicating potential volatility.
  • Novartis AG has a debt-to-equity ratio of 0.53, which, while manageable, may raise concerns about financial leverage compared to industry peers.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$262.38 billion
P/E Ratio
18.04
Consensus Rating
Hold
Consensus Price Target
$123.50 (-0.4% Downside)
Volume
1.15 million shares
Average Volume
1.80 million shares
Today's Range
$123.79
$124.48
50-Day Range
$113.55
$124.20
52-Week Range
$96.06
$124.83
Dividend Yield
2.13%
AstraZeneca stock logo

6. AstraZeneca NASDAQ:AZN

$79.12 -0.05 (-0.06%)
Closing price 08/18/2025 04:00 PM Eastern
Extended Trading
$79.27 +0.15 (+0.19%)
As of 05:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • The current stock price is around $79, which reflects a strong market capitalization of approximately $245 billion, indicating robust investor confidence.
  • AstraZeneca has shown impressive revenue growth, with a reported increase of over 16% compared to the same quarter last year, suggesting strong demand for its products.
  • The company has a solid earnings per share (EPS) of $1.09, meeting consensus estimates, which can indicate stability and reliability in its financial performance.

Cons of AstraZeneca

  • The company has a relatively high price-to-earnings (P/E) ratio of about 29.76, which may suggest that the stock is overvalued compared to its earnings.
  • AstraZeneca's current ratio is 0.86, indicating that it may have difficulty covering its short-term liabilities, which could pose a risk in times of financial strain.
  • Despite recent revenue growth, the company reported a decrease in EPS from the previous year, which could signal potential challenges in maintaining profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$245.54 billion
P/E Ratio
29.74
Consensus Rating
Moderate Buy
Consensus Price Target
$86.00 (+8.7% Upside)
Volume
3.02 million shares
Average Volume
5.67 million shares
Today's Range
$79.10
$79.78
50-Day Range
$68.72
$79.17
52-Week Range
$61.24
$87.68
Dividend Yield
1.28%
Novo Nordisk A/S stock logo

7. Novo Nordisk A/S NYSE:NVO

$53.81 +1.40 (+2.67%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$54.34 +0.53 (+0.99%)
As of 05:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • Recent upgrades from analysts, including a shift from "underperform" to "neutral" by BNP Paribas, suggest a more favorable outlook for the stock.
  • The current stock price is around $50, indicating a potential upside based on analysts' price targets, which suggest room for growth.
  • Institutional interest is strong, with significant purchases from entities like the Ontario Teachers Pension Plan Board, indicating confidence in the company's future performance.

Cons of Novo Nordisk A/S

  • Several analysts have downgraded their ratings, with firms like Guggenheim and HSBC moving to "hold," indicating caution among experts.
  • The stock has experienced significant volatility, with a 12-month high of $139.74 and a low of $45.05, suggesting potential risks for investors.
  • Market sentiment may be affected by broader economic conditions, which could impact the company's performance and stock price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$234.01 billion
P/E Ratio
14.78
Consensus Rating
Hold
Consensus Price Target
$83.75 (+55.6% Upside)
Volume
32.31 million shares
Average Volume
26.82 million shares
Today's Range
$53.75
$54.99
50-Day Range
$45.31
$81.07
52-Week Range
$45.05
$139.74
Dividend Yield
3.13%
Abbott Laboratories stock logo

8. Abbott Laboratories NYSE:ABT

$130.32 -1.43 (-1.09%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$130.33 +0.01 (+0.01%)
As of 05:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The company reported strong quarterly earnings, achieving $1.26 earnings per share, which met analysts' expectations, indicating stable financial performance.
  • Abbott Laboratories experienced a year-over-year revenue increase of 7.4%, reflecting growth in its business operations and market demand for its healthcare products.
  • The current stock price is around $120, which may present a favorable entry point for investors looking for growth in the healthcare sector.

Cons of Abbott Laboratories

  • Despite recent growth, the healthcare sector can be volatile, and Abbott Laboratories may face challenges from regulatory changes or market competition.
  • The company's net margin of 32.43% is impressive, but any decline in this figure could signal potential profitability issues in the future.
  • Abbott Laboratories operates in multiple segments, which can lead to complexities in management and potential inefficiencies that may affect overall performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$229.31 billion
P/E Ratio
16.33
Consensus Rating
Moderate Buy
Consensus Price Target
$144.47 (+10.9% Upside)
Volume
3.83 million shares
Average Volume
6.33 million shares
Today's Range
$130.16
$132.30
50-Day Range
$120.76
$138.13
52-Week Range
$110.33
$141.23
Dividend Yield
1.79%
Merck & Co., Inc. stock logo

9. Merck & Co., Inc. NYSE:MRK

$84.21 0.00 (0.00%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$84.55 +0.34 (+0.40%)
As of 05:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $82.77, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Merck has a strong market capitalization of approximately $206.75 billion, indicating a solid position in the industry and potential for stability.
  • Institutional investors own a significant portion of Merck's stock, with 76.07% held by hedge funds and other institutions, suggesting confidence in the company's future performance.

Cons of Merck & Co., Inc.

  • Analyst ratings have shown some caution, with recent downgrades from firms like Cantor Fitzgerald, which lowered its rating to "cautious," indicating potential concerns about future performance.
  • Merck's price target has been adjusted downwards by several analysts, with Wells Fargo reducing it from $97.00 to $90.00, suggesting a lack of confidence in short-term price appreciation.
  • The company has experienced fluctuations in stock performance, with a 52-week low of $73.31, indicating volatility that may deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$210.34 billion
P/E Ratio
12.98
Consensus Rating
Hold
Consensus Price Target
$107.44 (+27.6% Upside)
Volume
8.27 million shares
Average Volume
11.96 million shares
Today's Range
$84.08
$85.15
50-Day Range
$78.17
$84.82
52-Week Range
$73.31
$120.30
Dividend Yield
3.91%
Thermo Fisher Scientific stock logo

10. Thermo Fisher Scientific NYSE:TMO

$488.15 -0.86 (-0.18%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$488.76 +0.61 (+0.12%)
As of 05:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is around $490, which reflects a strong market position and potential for growth.
  • The company reported earnings per share of $5.36, exceeding analysts' expectations, indicating robust financial performance.
  • Thermo Fisher Scientific Inc. has a market capitalization of approximately $185 billion, showcasing its significant size and stability in the market.

Cons of Thermo Fisher Scientific

  • The stock has experienced fluctuations, with a 52-week high of $627.88 and a low of $385.46, indicating volatility that could concern risk-averse investors.
  • The price-to-earnings (P/E) ratio is 28.34, which may suggest that the stock is overvalued compared to its earnings, potentially limiting future price appreciation.
  • Insider selling has occurred, with executives selling shares, which could signal a lack of confidence in the company's short-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$184.66 billion
P/E Ratio
28.23
Consensus Rating
Moderate Buy
Consensus Price Target
$593.00 (+21.5% Upside)
Volume
2.21 million shares
Average Volume
3.06 million shares
Today's Range
$487.14
$493.24
50-Day Range
$390.17
$489.96
52-Week Range
$385.46
$627.88
Dividend Yield
0.35%
Intuitive Surgical stock logo

11. Intuitive Surgical NASDAQ:ISRG

$481.28 +1.02 (+0.21%)
Closing price 08/18/2025 04:00 PM Eastern
Extended Trading
$484.70 +3.42 (+0.71%)
As of 05:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The current stock price is around $508, which is significantly lower than its 12-month high, indicating potential for recovery and growth.
  • Intuitive Surgical, Inc. reported a strong quarterly earnings performance, with earnings per share exceeding expectations, showcasing robust financial health.
  • The company has demonstrated impressive revenue growth, with a year-over-year increase of over 21%, indicating strong demand for its products.

Cons of Intuitive Surgical

  • The stock has a high price-to-earnings ratio of 66.98, which may indicate that it is overvalued compared to its earnings, posing a risk for potential investors.
  • Insider selling activity has been noted, with significant shares sold recently, which could signal a lack of confidence from those within the company.
  • The price-to-earnings-growth ratio of 5.00 suggests that the stock may not be growing fast enough to justify its current valuation, which could deter some investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$172.16 billion
P/E Ratio
67.12
Consensus Rating
Moderate Buy
Consensus Price Target
$595.95 (+23.8% Upside)
Volume
1.64 million shares
Average Volume
2.17 million shares
Today's Range
$479.66
$487.20
50-Day Range
$469.81
$543.74
52-Week Range
$425.00
$616.00
Dividend Yield
N/A
Amgen stock logo

12. Amgen NASDAQ:AMGN

$292.62 -3.85 (-1.30%)
Closing price 08/18/2025 04:00 PM Eastern
Extended Trading
$290.39 -2.23 (-0.76%)
As of 05:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $289, reflecting a recent increase of 1.5%, which may indicate positive market sentiment towards the company.
  • Amgen Inc. has a strong dividend yield of 3.3%, providing a steady income stream for investors, which is particularly attractive in a low-interest-rate environment.
  • The company has a robust market capitalization of approximately $155.76 billion, indicating its significant presence and stability in the biotechnology sector.

Cons of Amgen

  • The company's recent insider selling, including a significant sale by a senior vice president, may raise concerns about the confidence of management in the company's future performance.
  • Amgen Inc. has a relatively high dividend payout ratio of 77.84%, which could limit its ability to reinvest in growth opportunities or respond to market changes.
  • Despite its strong market position, the biotechnology sector can be highly volatile, and Amgen Inc. is not immune to market fluctuations that could impact its stock price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$159.61 billion
P/E Ratio
23.93
Consensus Rating
Hold
Consensus Price Target
$303.76 (+3.8% Upside)
Volume
1.74 million shares
Average Volume
2.14 million shares
Today's Range
$292.30
$298.14
50-Day Range
$272.44
$309.22
52-Week Range
$253.30
$339.17
Dividend Yield
3.28%
Boston Scientific stock logo

13. Boston Scientific NYSE:BSX

$103.06 -0.11 (-0.11%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$103.02 -0.03 (-0.03%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The current stock price is around $103, which is near its 12-month high, indicating strong market performance and investor confidence.
  • Boston Scientific Co. reported a significant year-over-year revenue increase of 22.8%, showcasing robust growth in its business operations.
  • The company has a solid return on equity of 19.21%, reflecting effective management and profitability in generating returns for shareholders.

Cons of Boston Scientific

  • The price-to-earnings (P/E) ratio is quite high at 61.40, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider selling has been notable, with significant shares sold recently, which could signal a lack of confidence from those closest to the company.
  • The quick ratio of 0.82 suggests that the company may face challenges in meeting its short-term liabilities, which could raise concerns about liquidity.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$152.87 billion
P/E Ratio
61.35
Consensus Rating
Buy
Consensus Price Target
$117.50 (+14.0% Upside)
Volume
8.52 million shares
Average Volume
6.80 million shares
Today's Range
$102.18
$103.36
50-Day Range
$98.43
$107.51
52-Week Range
$77.71
$108.94
Dividend Yield
N/A
Danaher stock logo

14. Danaher NYSE:DHR

$209.32 -1.61 (-0.76%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$208.38 -0.94 (-0.45%)
As of 05:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The current stock price is around $205, which may present a buying opportunity for investors looking for growth potential.
  • Danaher Co. has consistently outperformed earnings expectations, recently reporting earnings per share that exceeded analyst estimates, indicating strong financial health.
  • The company has a robust market capitalization of approximately $147 billion, suggesting stability and a strong position in the market.

Cons of Danaher

  • Several analysts have recently lowered their target prices for Danaher Co., which may indicate concerns about future performance.
  • The stock has a relatively high price-to-earnings ratio, suggesting that it may be overvalued compared to its earnings, which could deter value-focused investors.
  • Despite positive earnings reports, the stock has experienced fluctuations, which may indicate volatility and risk for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$151.04 billion
P/E Ratio
44.54
Consensus Rating
Moderate Buy
Consensus Price Target
$247.61 (+18.3% Upside)
Volume
2.86 million shares
Average Volume
4.61 million shares
Today's Range
$208.70
$212.15
50-Day Range
$188.23
$210.84
52-Week Range
$171.00
$279.90
Dividend Yield
0.61%
Gilead Sciences stock logo

15. Gilead Sciences NASDAQ:GILD

$117.99 -0.38 (-0.32%)
Closing price 08/18/2025 04:00 PM Eastern
Extended Trading
$118.70 +0.70 (+0.60%)
As of 05:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The current stock price is around $118, reflecting a strong market position and investor confidence in the company's future growth potential.
  • Recent analyst upgrades indicate positive sentiment, with multiple firms raising their target prices, suggesting that the stock may have further upside.
  • Gilead Sciences, Inc. has a solid market capitalization of approximately $146.87 billion, indicating stability and a strong presence in the biopharmaceutical sector.

Cons of Gilead Sciences

  • Insider selling has been notable, with significant shares sold recently, which may raise concerns about the confidence of those within the company.
  • The company has a relatively low insider ownership of only 0.27%, which could indicate a lack of alignment between management and shareholder interests.
  • Despite recent upgrades, the stock has shown volatility, with a one-year high of $121.83 and a low of $72.89, suggesting potential risks for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$146.87 billion
P/E Ratio
23.50
Consensus Rating
Moderate Buy
Consensus Price Target
$114.82 (-2.7% Downside)
Volume
4.47 million shares
Average Volume
6.51 million shares
Today's Range
$117.85
$119.37
50-Day Range
$105.93
$120.47
52-Week Range
$73.27
$121.83
Dividend Yield
2.65%
Stryker stock logo

16. Stryker NYSE:SYK

$381.91 0.00 (0.00%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$379.00 -2.91 (-0.76%)
As of 08/18/2025 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The current stock price is around $377.56, reflecting a stable market position and potential for growth.
  • Stryker Co. reported earnings per share of $3.13, exceeding analysts' expectations, indicating strong financial performance.
  • The company achieved a revenue of $6.02 billion for the quarter, surpassing estimates, which suggests robust demand for its medical technology products.

Cons of Stryker

  • The stock has a high price-to-earnings (P/E) ratio of 50.00, which may suggest that it is overvalued compared to its earnings, posing a risk for new investors.
  • Despite strong revenue growth, the net margin of 12.25% indicates that profit margins may be under pressure, which could affect future earnings.
  • Insider selling, such as the recent sale of 200,000 shares by a director, may raise concerns about the company's future prospects and insider confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$146.01 billion
P/E Ratio
50.58
Consensus Rating
Moderate Buy
Consensus Price Target
$430.10 (+12.6% Upside)
Volume
1.10 million shares
Average Volume
1.33 million shares
Today's Range
$380.57
$382.99
50-Day Range
$373.22
$403.34
52-Week Range
$329.16
$406.19
Dividend Yield
0.89%
Pfizer stock logo

17. Pfizer NYSE:PFE

$25.07 -0.07 (-0.28%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$25.11 +0.04 (+0.16%)
As of 05:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $25.14, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Pfizer Inc. recently reported earnings that exceeded analysts' expectations, indicating strong financial performance and potential for future growth.
  • The company has a solid market capitalization of approximately $142.93 billion, reflecting its stability and established presence in the industry.

Cons of Pfizer

  • Despite recent earnings growth, the company has a high payout ratio of 91.49%, which may limit its ability to reinvest in growth opportunities.
  • Analysts have issued a mix of ratings, with some indicating a "neutral" or "underperform" stance, suggesting uncertainty about the stock's future performance.
  • The stock has experienced volatility, with a twelve-month high of $30.43 and a low of $20.92, indicating potential risks for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$142.93 billion
P/E Ratio
13.34
Consensus Rating
Hold
Consensus Price Target
$28.12 (+12.2% Upside)
Volume
35.61 million shares
Average Volume
45.00 million shares
Today's Range
$25.01
$25.23
50-Day Range
$23.27
$25.77
52-Week Range
$20.92
$30.43
Dividend Yield
6.84%
Sanofi stock logo

18. Sanofi NASDAQ:SNY

$49.84 +0.07 (+0.14%)
Closing price 08/18/2025 04:00 PM Eastern
Extended Trading
$50.38 +0.54 (+1.08%)
As of 05:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi has received multiple "buy" ratings from analysts, indicating strong confidence in its future performance.
  • The current stock price is around $49.77, which may present a buying opportunity for investors looking for value.
  • Sanofi reported a revenue of $11.34 billion in its latest quarter, significantly exceeding analysts' expectations, showcasing strong operational performance.

Cons of Sanofi

  • Sanofi's earnings per share (EPS) of $0.90 for the latest quarter fell short of the consensus estimate, indicating potential challenges in meeting market expectations.
  • The company's revenue decreased by 7.0% compared to the same quarter last year, which may raise concerns about its growth trajectory.
  • Sanofi has a relatively low beta of 0.48, suggesting it may not be as responsive to market movements, which could limit potential gains in a bullish market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$122.21 billion
P/E Ratio
11.98
Consensus Rating
Buy
Consensus Price Target
$62.00 (+24.4% Upside)
Volume
3.95 million shares
Average Volume
2.66 million shares
Today's Range
$49.64
$50.15
50-Day Range
$45.64
$50.83
52-Week Range
$44.73
$60.12
Dividend Yield
3.21%
Medtronic stock logo

19. Medtronic NYSE:MDT

$92.74 -0.29 (-0.31%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$92.94 +0.20 (+0.22%)
As of 04:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The current stock price is around $92, which is near the lower end of its 52-week range, potentially offering a buying opportunity for investors looking for value.
  • Medtronic plc recently reported strong quarterly earnings, with earnings per share of $1.62, surpassing analyst expectations, indicating robust financial performance.
  • The company has a solid revenue growth of 3.9% year-over-year, reflecting its ability to expand and adapt in the competitive medical technology market.

Cons of Medtronic

  • The stock has experienced fluctuations, with a 52-week high of $96.25, indicating potential volatility that could concern risk-averse investors.
  • Medtronic plc has a relatively high payout ratio of 78.45%, which may raise concerns about the sustainability of its dividend payments in the long term.
  • Despite recent positive earnings, the company operates in a highly competitive industry, which could impact future growth and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$119.23 billion
P/E Ratio
25.62
Consensus Rating
Moderate Buy
Consensus Price Target
$98.19 (+5.9% Upside)
Volume
11.58 million shares
Average Volume
6.46 million shares
Today's Range
$92.51
$93.32
50-Day Range
$85.68
$92.98
52-Week Range
$79.29
$96.25
Dividend Yield
3.05%
Vertex Pharmaceuticals stock logo

20. Vertex Pharmaceuticals NASDAQ:VRTX

$389.88 -2.91 (-0.74%)
Closing price 08/18/2025 04:00 PM Eastern
Extended Trading
$389.40 -0.48 (-0.12%)
As of 05:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The current stock price is around $392.79, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
  • Vertex Pharmaceuticals Incorporated reported strong quarterly earnings, with earnings per share (EPS) of $4.52, exceeding analysts' expectations, indicating robust financial health and operational efficiency.
  • The company has shown a year-over-year revenue increase of 11.3%, reflecting its ability to grow and expand its market presence effectively.

Cons of Vertex Pharmaceuticals

  • The stock has experienced volatility, with a 52-week range between $362.50 and $519.88, which may indicate potential risks for investors concerned about price fluctuations.
  • Despite strong earnings, the company has a relatively high price-to-earnings (P/E) ratio of 28.08, which could suggest that the stock is overvalued compared to its earnings.
  • Analysts have varying opinions, with some firms lowering their price targets, which may create uncertainty about the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$100.71 billion
P/E Ratio
27.87
Consensus Rating
Moderate Buy
Consensus Price Target
$497.10 (+27.5% Upside)
Volume
1.38 million shares
Average Volume
2.39 million shares
Today's Range
$389.21
$395.61
50-Day Range
$366.54
$479.53
52-Week Range
$362.50
$519.88
Dividend Yield
N/A
Bristol Myers Squibb stock logo

21. Bristol Myers Squibb NYSE:BMY

$48.19 -0.25 (-0.52%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$48.10 -0.09 (-0.19%)
As of 05:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The company recently reported strong quarterly earnings, with earnings per share significantly exceeding analyst expectations, indicating robust financial health and operational efficiency.
  • Bristol-Myers Squibb has a diverse portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers and autoimmune diseases, which positions it well for future growth.
  • The current stock price is around $47, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.

Cons of Bristol Myers Squibb

  • The company has a high debt-to-equity ratio of 2.54, which may indicate financial risk and could limit its ability to invest in new projects or weather economic downturns.
  • Recent revenue growth has been modest, with only a slight year-over-year increase, suggesting potential challenges in maintaining momentum in a competitive market.
  • With a price-to-earnings ratio of 19.54, the stock may be considered overvalued compared to industry peers, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$98.60 billion
P/E Ratio
19.43
Consensus Rating
Hold
Consensus Price Target
$56.38 (+17.0% Upside)
Volume
7.87 million shares
Average Volume
12.74 million shares
Today's Range
$48.08
$48.71
50-Day Range
$43.37
$50.68
52-Week Range
$42.96
$63.33
Dividend Yield
5.12%
HCA Healthcare stock logo

22. HCA Healthcare NYSE:HCA

$393.86 -1.94 (-0.49%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$393.58 -0.28 (-0.07%)
As of 08/18/2025 04:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The current stock price is around $393.86, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • HCA Healthcare, Inc. reported earnings per share of $6.84 for the latest quarter, surpassing analysts' expectations, which suggests strong financial performance.
  • The company has shown a year-over-year revenue growth of 6.4%, indicating a solid upward trend in its business operations.

Cons of HCA Healthcare

  • The company has a high debt-to-equity ratio of 69.07, which may indicate financial risk and reliance on borrowed funds.
  • HCA Healthcare, Inc. has a negative return on equity of over 7,363.11%, suggesting inefficiencies in generating profit from shareholders' equity.
  • Analysts have issued mixed ratings, with some downgrading their outlook, which could signal uncertainty about future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$92.61 billion
P/E Ratio
16.56
Consensus Rating
Moderate Buy
Consensus Price Target
$398.58 (+1.2% Upside)
Volume
1.02 million shares
Average Volume
1.55 million shares
Today's Range
$393.32
$397.40
50-Day Range
$334.26
$395.83
52-Week Range
$289.98
$417.14
Dividend Yield
0.73%
CVS Health stock logo

23. CVS Health NYSE:CVS

$70.12 +1.52 (+2.22%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$70.24 +0.12 (+0.17%)
As of 05:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • The company recently reported earnings per share of $1.81, significantly exceeding analysts' expectations, indicating strong financial performance.
  • CVS Health Co. has shown a year-over-year revenue increase of 8.4%, reflecting growth and resilience in its business model.
  • The current stock price is around $75, which is considered attractive given the company's solid fundamentals and growth prospects.

Cons of CVS Health

  • The company's net margin is relatively low at 1.17%, which may indicate challenges in profitability compared to competitors.
  • CVS Health Co. experienced a slight decline in earnings per share compared to the same quarter last year, which could raise concerns about its growth trajectory.
  • Insider ownership is only 1.22%, which may suggest a lack of confidence from those closest to the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$87.01 billion
P/E Ratio
19.59
Consensus Rating
Buy
Consensus Price Target
$76.67 (+9.3% Upside)
Volume
9.24 million shares
Average Volume
9.00 million shares
Today's Range
$69.40
$71.05
50-Day Range
$58.82
$70.12
52-Week Range
$43.56
$72.51
Dividend Yield
3.88%
McKesson stock logo

24. McKesson NYSE:MCK

$670.82 -2.23 (-0.33%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$671.06 +0.24 (+0.04%)
As of 08/18/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $720, reflecting a strong market position and investor confidence in the company's growth potential.
  • Recent earnings reports show a significant year-over-year revenue increase of over 23%, indicating robust business performance and demand for healthcare services.
  • Analysts have a consensus rating of "Moderate Buy" with multiple firms issuing buy ratings and target prices above the current stock price, suggesting potential for upward movement.

Cons of McKesson

  • The company reported earnings per share that missed consensus estimates, which may raise concerns about its ability to meet market expectations consistently.
  • McKesson Co. has a negative return on equity, indicating that the company is not generating profit effectively from its equity base, which could deter some investors.
  • Despite revenue growth, the net margin is relatively low at 0.84%, suggesting that profitability may be a concern in the competitive healthcare market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$83.72 billion
P/E Ratio
26.75
Consensus Rating
Moderate Buy
Consensus Price Target
$719.27 (+7.2% Upside)
Volume
512,311 shares
Average Volume
890,530 shares
Today's Range
$668.50
$677.00
50-Day Range
$658.78
$735.41
52-Week Range
$464.42
$737.89
Dividend Yield
0.42%
GSK stock logo

25. GSK NYSE:GSK

$39.05 -0.31 (-0.79%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$39.19 +0.14 (+0.36%)
As of 05:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $37.65, which is near the average price target of $37.38 set by analysts, indicating potential for stability and growth.
  • GSK plc recently reported earnings per share of $1.23, surpassing analysts' expectations, which reflects strong financial performance and effective management.
  • The company has a solid market capitalization of approximately $76.81 billion, suggesting a robust position in the pharmaceutical industry.

Cons of GSK

  • The company has a relatively high debt-to-equity ratio of 1.07, which may indicate financial risk if the company faces downturns or increased interest rates.
  • GSK plc's current ratio of 0.87 suggests that the company may have difficulty meeting its short-term liabilities, which could raise concerns about liquidity.
  • Despite recent earnings growth, the revenue increase of only 1.3% year-over-year may not be sufficient to attract growth-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$80.26 billion
P/E Ratio
18.08
Consensus Rating
Reduce
Consensus Price Target
$37.38 (-4.3% Downside)
Volume
2.44 million shares
Average Volume
4.59 million shares
Today's Range
$39.02
$39.36
50-Day Range
$36.21
$42.50
52-Week Range
$31.72
$44.67
Dividend Yield
4.36%
Cigna Group stock logo

26. Cigna Group NYSE:CI

$298.88 +2.02 (+0.68%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$297.50 -1.38 (-0.46%)
As of 05:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The current stock price is around $290, which may present a buying opportunity for investors looking for value in the health services sector.
  • The Cigna Group has recently reported strong earnings, with earnings per share exceeding expectations, indicating robust financial health and operational efficiency.
  • Analysts have a positive outlook on the stock, with a majority rating it as a buy or strong buy, suggesting confidence in its future performance.

Cons of Cigna Group

  • The stock has experienced fluctuations, with a 12-month high of $370.83 and a low of $256.89, indicating potential volatility that could affect investment stability.
  • Some analysts have recently adjusted their price targets downward, which may reflect concerns about future growth prospects or market conditions.
  • The company's current ratio is 0.71, suggesting that it may face challenges in meeting short-term liabilities, which could impact financial flexibility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$79.24 billion
P/E Ratio
16.31
Consensus Rating
Buy
Consensus Price Target
$378.33 (+26.6% Upside)
Volume
1.96 million shares
Average Volume
2.16 million shares
Today's Range
$297.50
$303.12
50-Day Range
$262.26
$334.71
52-Week Range
$256.89
$370.83
Dividend Yield
2.08%
Elevance Health stock logo

27. Elevance Health NYSE:ELV

$310.03 +0.46 (+0.15%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$310.43 +0.40 (+0.13%)
As of 05:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$69.71 billion
P/E Ratio
13.19
Consensus Rating
Moderate Buy
Consensus Price Target
$413.81 (+33.5% Upside)
Volume
2.51 million shares
Average Volume
2.82 million shares
Today's Range
$309.23
$316.59
50-Day Range
$274.10
$395.76
52-Week Range
$273.71
$567.26
Dividend Yield
2.32%
Zoetis stock logo

28. Zoetis NYSE:ZTS

$152.28 -1.83 (-1.19%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$152.64 +0.36 (+0.24%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • Zoetis Inc. recently reported earnings per share of $1.76, exceeding analysts' expectations, which indicates strong financial performance and potential for future growth.
  • The company has demonstrated a solid revenue increase of 4.2% compared to the same quarter last year, reflecting its ability to grow in a competitive market.
  • With a return on equity of 56.90%, Zoetis Inc. shows effective management and profitability, suggesting that the company is generating significant returns on shareholders' investments.

Cons of Zoetis

  • The stock has a price-to-earnings ratio of 26.53, which may suggest that it is overvalued compared to its earnings, potentially limiting future price appreciation.
  • Despite strong performance, the company's net margin of 27.83% may indicate that there are pressures on profitability, which could affect future earnings.
  • Zoetis Inc. has a debt-to-equity ratio of 1.05, suggesting that the company has a significant amount of debt relative to its equity, which could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$68.30 billion
P/E Ratio
26.21
Consensus Rating
Moderate Buy
Consensus Price Target
$202.43 (+32.9% Upside)
Volume
2.16 million shares
Average Volume
3.68 million shares
Today's Range
$151.60
$154.94
50-Day Range
$145.76
$168.64
52-Week Range
$139.70
$200.33
Dividend Yield
1.30%
Regeneron Pharmaceuticals stock logo

29. Regeneron Pharmaceuticals NASDAQ:REGN

$573.91 -6.50 (-1.12%)
Closing price 08/18/2025 04:00 PM Eastern
Extended Trading
$577.00 +3.09 (+0.54%)
As of 05:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The company recently reported strong earnings, with earnings per share significantly exceeding analyst expectations, indicating robust financial health and operational efficiency.
  • Regeneron Pharmaceuticals, Inc. has a solid market capitalization of approximately $61 billion, suggesting a stable and established presence in the biopharmaceutical sector.
  • The current stock price is around $720, which may present a buying opportunity for investors looking for growth potential in a well-performing company.

Cons of Regeneron Pharmaceuticals

  • Despite recent successes, the stock has experienced fluctuations, and the price target set by analysts varies widely, indicating uncertainty in future performance.
  • Regeneron Pharmaceuticals, Inc. has a relatively low dividend yield of 0.6%, which may not attract income-focused investors looking for higher returns from dividends.
  • The company faces intense competition in the biopharmaceutical industry, which could impact its market share and profitability in the long term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$61.52 billion
P/E Ratio
14.46
Consensus Rating
Moderate Buy
Consensus Price Target
$829.65 (+44.6% Upside)
Volume
768,031 shares
Average Volume
976,576 shares
Today's Range
$573.81
$585.00
50-Day Range
$508.86
$580.41
52-Week Range
$476.49
$1,211.20
Dividend Yield
0.61%
Alnylam Pharmaceuticals stock logo

30. Alnylam Pharmaceuticals NASDAQ:ALNY

$456.87 +7.96 (+1.77%)
Closing price 08/18/2025 04:00 PM Eastern
Extended Trading
$460.13 +3.26 (+0.71%)
As of 05:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The company recently reported earnings that exceeded expectations, showcasing a positive trend in financial performance.
  • Alnylam Pharmaceuticals, Inc. has a strong market capitalization, indicating robust investor confidence and potential for growth.
  • Recent analyst upgrades have set higher price targets for the stock, suggesting that market experts see significant upside potential.

Cons of Alnylam Pharmaceuticals

  • The company has a negative PE ratio, indicating that it is currently not profitable, which can be a red flag for potential investors.
  • Alnylam Pharmaceuticals, Inc. has a high debt-to-equity ratio, suggesting that it relies heavily on debt financing, which can increase financial risk.
  • Recent insider selling by the CEO may raise concerns about the company's future performance and management's confidence in its prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$58.84 billion
P/E Ratio
-184.97
Consensus Rating
Moderate Buy
Consensus Price Target
$405.33 (-11.3% Downside)
Volume
1.61 million shares
Average Volume
1.32 million shares
Today's Range
$447.10
$457.92
50-Day Range
$298.58
$456.87
52-Week Range
$205.87
$457.92
Dividend Yield
N/A
Cencora stock logo

31. Cencora NYSE:COR

$290.45 -2.37 (-0.81%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$289.56 -0.88 (-0.30%)
As of 08/18/2025 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The company recently reported earnings per share (EPS) of $4.00, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • Cencora, Inc. has a solid revenue of approximately $80.66 billion for the latest quarter, showing an increase compared to the previous year, suggesting a positive trend in sales.
  • The current stock price is around $355, reflecting a favorable valuation based on recent analyst upgrades and positive market sentiment.

Cons of Cencora

  • The company's net margin is relatively low at 0.60%, which may raise concerns about profitability and operational efficiency.
  • Despite recent growth, the pharmaceutical distribution sector can be highly competitive and subject to regulatory changes, which could impact future performance.
  • While the dividend yield is currently at 0.8%, it may not be sufficient to attract investors looking for higher income from their investments.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$56.77 billion
P/E Ratio
29.88
Consensus Rating
Moderate Buy
Consensus Price Target
$311.25 (+7.2% Upside)
Volume
1.19 million shares
Average Volume
1.23 million shares
Today's Range
$290.22
$295.58
50-Day Range
$278.18
$302.43
52-Week Range
$218.65
$309.35
Dividend Yield
0.75%
Becton, Dickinson and Company stock logo

32. Becton, Dickinson and Company NYSE:BDX

$195.22 -0.72 (-0.37%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$195.04 -0.18 (-0.09%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The company recently reported strong quarterly earnings, with earnings per share (EPS) of $3.68, surpassing analysts' expectations, indicating robust financial performance.
  • Revenue growth of 10.4% year-over-year demonstrates the company's ability to expand its market presence and increase sales effectively.
  • The current stock price is around $195, which is relatively stable compared to its 12-month high of $251.99, suggesting potential for recovery and growth.

Cons of Becton, Dickinson and Company

  • The stock has experienced insider selling, with executives reducing their holdings, which may signal a lack of confidence in the company's short-term prospects.
  • Some analysts have downgraded their ratings, reflecting concerns about the company's future performance and market conditions.
  • The stock's price-to-earnings (P/E) ratio of 35.11 is relatively high, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$56.16 billion
P/E Ratio
35.11
Consensus Rating
Hold
Consensus Price Target
$211.44 (+8.3% Upside)
Volume
1.76 million shares
Average Volume
2.82 million shares
Today's Range
$194.96
$197.42
50-Day Range
$168.54
$196.12
52-Week Range
$163.33
$251.99
Dividend Yield
2.12%
IDEXX Laboratories stock logo

33. IDEXX Laboratories NASDAQ:IDXX

$637.86 -12.98 (-1.99%)
Closing price 08/18/2025 04:00 PM Eastern
Extended Trading
$641.24 +3.38 (+0.53%)
As of 05:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $652, reflecting a strong market position and investor confidence in the company's growth potential.
  • IDEXX Laboratories, Inc. reported a significant increase in revenue, up 10.6% year-over-year, indicating robust demand for its products and services.
  • The company has a high return on equity of 64.42%, suggesting efficient management and strong profitability, which can lead to higher shareholder returns.

Cons of IDEXX Laboratories

  • The stock has a high P/E ratio of 54.31, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider selling has been notable, with executives selling over 52,000 shares recently, which could signal a lack of confidence in the stock's short-term performance.
  • The company has a relatively low quick ratio of 0.79, suggesting potential liquidity issues that could affect its ability to meet short-term obligations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$52.07 billion
P/E Ratio
53.11
Consensus Rating
Moderate Buy
Consensus Price Target
$649.44 (+1.8% Upside)
Volume
437,032 shares
Average Volume
855,688 shares
Today's Range
$637.08
$652.08
50-Day Range
$514.61
$682.78
52-Week Range
$356.14
$688.12
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

34. Takeda Pharmaceutical NYSE:TAK

$15.18 +0.18 (+1.22%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$15.20 +0.01 (+0.08%)
As of 04:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price is around $14.77, which reflects a recent increase in trading volume, indicating heightened investor interest.
  • Takeda Pharmaceutical Company Limited has shown strong revenue performance, with quarterly revenues recently reported at approximately $7.34 billion, although slightly below analyst expectations.
  • The company has a solid market capitalization of about $46.98 billion, suggesting a stable position in the pharmaceutical industry.

Cons of Takeda Pharmaceutical

  • The company recently reported earnings per share (EPS) of $0.16, which fell short of the consensus estimate, raising concerns about its profitability.
  • Takeda Pharmaceutical Company Limited's revenue for the last quarter was below analyst expectations, which may indicate challenges in meeting growth targets.
  • With a debt-to-equity ratio of 0.60, while manageable, it suggests that the company is somewhat reliant on debt financing, which could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$47.73 billion
P/E Ratio
50.61
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
3.56 million shares
Average Volume
5.50 million shares
Today's Range
$15.08
$15.19
50-Day Range
$13.60
$15.55
52-Week Range
$12.80
$15.53
Dividend Yield
3.68%
Edwards Lifesciences stock logo

35. Edwards Lifesciences NYSE:EW

$78.30 +0.04 (+0.05%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$78.47 +0.17 (+0.22%)
As of 04:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The current stock price is around $78, which is near its 52-week low of $64, potentially offering a buying opportunity for investors looking for value.
  • Recent quarterly earnings showed a strong performance with earnings per share of $0.67, exceeding analyst expectations, indicating robust financial health.
  • The company reported a revenue increase of 11.9% year-over-year, suggesting strong growth potential in its market segment.

Cons of Edwards Lifesciences

  • Insider selling has been observed, with significant shares sold recently, which may indicate a lack of confidence among company executives.
  • The stock has experienced a decrease in ownership by insiders, which could suggest potential concerns about the company's future performance.
  • Despite strong earnings, the stock's price-to-earnings ratio of 11.26 may not reflect future growth expectations, leading to potential overvaluation risks.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.95 billion
P/E Ratio
11.27
Consensus Rating
Moderate Buy
Consensus Price Target
$85.90 (+9.7% Upside)
Volume
4.29 million shares
Average Volume
4.77 million shares
Today's Range
$77.65
$78.94
50-Day Range
$73.31
$81.15
52-Week Range
$64.00
$83.00
Dividend Yield
N/A
Veeva Systems stock logo

36. Veeva Systems NYSE:VEEV

$282.82 +2.22 (+0.79%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$283.30 +0.47 (+0.17%)
As of 05:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The current stock price is around $289, which reflects strong market interest and potential for growth.
  • Veeva Systems Inc. reported earnings per share (EPS) of $1.97, exceeding analysts' expectations, indicating robust financial performance.
  • The company achieved a year-over-year revenue increase of 16.7%, showcasing its ability to grow and adapt in the competitive life sciences software market.

Cons of Veeva Systems

  • Insider selling activity has been noted, with significant shares sold by key executives, which may raise concerns about their confidence in the company's future performance.
  • The stock has experienced fluctuations, with a 52-week high of $296.72 and a low of $185.51, indicating potential volatility that could affect investment stability.
  • Despite recent growth, the competitive landscape in the cloud-based software sector for life sciences is intensifying, which could impact future market share.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.86 billion
P/E Ratio
59.92
Consensus Rating
Moderate Buy
Consensus Price Target
$274.17 (-3.1% Downside)
Volume
1.23 million shares
Average Volume
1.16 million shares
Today's Range
$278.10
$285.52
50-Day Range
$275.24
$292.77
52-Week Range
$192.51
$296.72
Dividend Yield
N/A
Haleon stock logo

37. Haleon NYSE:HLN

$9.69 +0.04 (+0.41%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$9.69 0.00 (-0.01%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • Recent upgrades from multiple analysts, including a strong-buy rating from BNP Paribas, indicate positive market sentiment and potential for stock appreciation.
  • The current stock price is around $9.65, which may present a buying opportunity for investors looking for value in the consumer healthcare sector.
  • Haleon plc has recently increased its semi-annual dividend to $0.0555 per share, reflecting a commitment to returning value to shareholders.

Cons of Haleon

  • Despite recent upgrades, the stock has experienced a decline of about 1.6%, which may raise concerns about short-term volatility.
  • The company has a relatively high P/E ratio of 24.74, which could indicate that the stock is overvalued compared to its earnings.
  • Haleon plc's debt-to-equity ratio of 0.53 suggests a moderate level of debt, which could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.31 billion
P/E Ratio
24.85
Consensus Rating
Moderate Buy
Consensus Price Target
$12.33 (+27.2% Upside)
Volume
7.48 million shares
Average Volume
10.98 million shares
Today's Range
$9.64
$9.75
50-Day Range
$9.28
$11.01
52-Week Range
$8.86
$11.42
Dividend Yield
1.15%
Alcon stock logo

38. Alcon NYSE:ALC

$88.32 +0.61 (+0.70%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$88.79 +0.47 (+0.53%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $91.50, reflecting a strong performance in the market.
  • Alcon Inc. has shown a positive fifty-two week performance, indicating a growth trend that may attract investors.
  • Institutional ownership is significant, suggesting confidence from large investors in the company's future prospects.

Cons of Alcon

  • Despite recent positive trends, the average daily volume has decreased, which may indicate reduced trading interest.
  • The company has experienced fluctuations in short interest, which can create volatility and uncertainty in the stock price.
  • There has been a notable month-to-month change in shares shorted, which could reflect shifting investor confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.26 billion
P/E Ratio
39.25
Consensus Rating
Moderate Buy
Consensus Price Target
$104.25 (+18.0% Upside)
Volume
2.41 million shares
Average Volume
1.68 million shares
Today's Range
$87.60
$89.08
50-Day Range
$84.12
$92.25
52-Week Range
$80.48
$101.10
Dividend Yield
N/A
ResMed stock logo

39. ResMed NYSE:RMD

$286.17 +1.28 (+0.45%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$284.50 -1.66 (-0.58%)
As of 08/18/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • The company recently increased its quarterly dividend from $0.53 to $0.60 per share, reflecting a commitment to returning value to shareholders. This increase represents an annualized dividend of $2.40, which can be attractive for income-focused investors.
  • ResMed Inc. is projected to post an earnings per share (EPS) of 9.47 for the current year, indicating strong profitability and potential for growth, which can enhance investor confidence.
  • Institutional investors own approximately 54.98% of ResMed Inc.'s stock, suggesting strong institutional support and confidence in the company's future performance.

Cons of ResMed

  • Insider selling has been observed, with corporate insiders selling 27,063 shares worth over $7 million in the last 90 days, which may raise concerns about the company's future outlook from those closest to it.
  • Despite recent upgrades, there is still a mix of ratings from analysts, with one analyst issuing a sell rating, indicating that not all market participants are confident in the stock's future performance.
  • The dividend payout ratio is 22.29%, which, while sustainable, may limit the company's ability to reinvest in growth opportunities compared to companies with lower payout ratios.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$41.71 billion
P/E Ratio
30.09
Consensus Rating
Moderate Buy
Consensus Price Target
$274.83 (-4.0% Downside)
Volume
550,660 shares
Average Volume
1.19 million shares
Today's Range
$284.42
$287.83
50-Day Range
$249.16
$291.30
52-Week Range
$199.92
$293.08
Dividend Yield
0.84%
argenex stock logo

40. argenex NASDAQ:ARGX

$661.32 +7.49 (+1.15%)
Closing price 08/18/2025 04:00 PM Eastern
Extended Trading
$656.82 -4.50 (-0.68%)
As of 05:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The stock has a strong consensus rating of "Buy" from analysts, indicating positive sentiment and potential for growth.
  • Recent price targets from analysts suggest significant upside potential, with estimates reaching as high as $830.00.
  • The current stock price is around $653.83, reflecting a solid position within its 52-week range, which has seen a low of $510.05 and a high of $696.21.

Cons of argenex

  • The stock has experienced volatility, with fluctuations in trading volume that could indicate uncertainty among investors.
  • Despite positive analyst ratings, the stock's price-to-earnings ratio is relatively high, which may suggest it is overvalued compared to its earnings potential.
  • Recent trading activity shows mixed performance, with the stock only slightly up by 0.2% in recent sessions, indicating potential stagnation.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.01 billion
P/E Ratio
33.91
Consensus Rating
Buy
Consensus Price Target
$746.81 (+12.9% Upside)
Volume
308,199 shares
Average Volume
448,185 shares
Today's Range
$652.65
$669.53
50-Day Range
$537.92
$690.32
52-Week Range
$510.05
$696.21
Dividend Yield
N/A
Cardinal Health stock logo

41. Cardinal Health NYSE:CAH

$149.70 +0.09 (+0.06%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$148.82 -0.87 (-0.58%)
As of 08/18/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The company reported earnings per share of $2.08 for the latest quarter, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • Cardinal Health, Inc. has shown a year-over-year revenue increase of 0.5%, suggesting stability and resilience in its business operations.
  • Analysts forecast an earnings per share of 7.95 for the current year, indicating positive growth expectations for the company.

Cons of Cardinal Health

  • The company has a negative return on equity of 68.84%, which may raise concerns about its efficiency in generating profits from shareholders' equity.
  • Despite a slight revenue increase, the total revenue of $60.16 billion fell short of analysts' expectations, indicating potential challenges in meeting market demands.
  • The net margin of 0.70% is relatively low, suggesting that the company may not be effectively converting revenue into profit.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.73 billion
P/E Ratio
23.21
Consensus Rating
Moderate Buy
Consensus Price Target
$163.20 (+9.0% Upside)
Volume
2.06 million shares
Average Volume
2.38 million shares
Today's Range
$148.52
$151.20
50-Day Range
$146.51
$167.92
52-Week Range
$106.54
$168.44
Dividend Yield
1.37%
BeOne Medicines stock logo

42. BeOne Medicines NASDAQ:ONC

$319.32 -2.04 (-0.63%)
As of 08/18/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$35.22 billion
P/E Ratio
-184.58
Consensus Rating
Buy
Consensus Price Target
$330.89 (+3.6% Upside)
Volume
595,229 shares
Average Volume
413,984 shares
Today's Range
$318.69
$330.63
50-Day Range
$240.99
$321.36
52-Week Range
$170.99
$330.63
Dividend Yield
N/A
Humana stock logo

43. Humana NYSE:HUM

$287.75 +1.36 (+0.47%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$288.68 +0.93 (+0.32%)
As of 08/18/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $287.90, which reflects a significant increase from its 12-month low, indicating potential for growth.
  • Humana Inc. reported a revenue increase of 9.6% year-over-year, showcasing strong business performance and demand for its insurance products.
  • The company has a solid market capitalization of approximately $34.49 billion, suggesting stability and investor confidence in its operations.

Cons of Humana

  • The company missed its earnings per share estimate in the last quarter, which may raise concerns about its short-term profitability.
  • Humana Inc. has a relatively high price-to-earnings (P/E) ratio of 22.01, which could suggest that the stock is overvalued compared to its earnings.
  • Recent analyst reports have shown mixed ratings, with some downgrades indicating uncertainty about the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.44 billion
P/E Ratio
22.08
Consensus Rating
Hold
Consensus Price Target
$281.43 (-2.2% Downside)
Volume
1.30 million shares
Average Volume
1.95 million shares
Today's Range
$287.00
$290.87
50-Day Range
$220.08
$287.75
52-Week Range
$206.87
$382.72
Dividend Yield
1.26%
Agilent Technologies stock logo

44. Agilent Technologies NYSE:A

$118.44 -0.76 (-0.64%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$119.99 +1.55 (+1.31%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The current stock price is around $116.61, which reflects a stable position in the market and potential for growth.
  • Agilent Technologies, Inc. has recently reported strong quarterly earnings, exceeding analysts' expectations, indicating robust financial health and operational efficiency.
  • With a market capitalization of approximately $33.13 billion, the company is well-positioned in the medical research sector, suggesting stability and growth potential.

Cons of Agilent Technologies

  • Despite recent positive earnings, the stock has shown volatility, with a beta of 1.22, indicating that it may be more volatile than the market.
  • Some analysts have reduced their price targets, which could signal concerns about future growth potential and market conditions.
  • The company has a relatively high P/E ratio of 28.79, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.86 billion
P/E Ratio
29.24
Consensus Rating
Moderate Buy
Consensus Price Target
$139.77 (+18.0% Upside)
Volume
1.02 million shares
Average Volume
1.42 million shares
Today's Range
$118.15
$119.60
50-Day Range
$112.12
$124.18
52-Week Range
$96.43
$153.84
Dividend Yield
0.83%
GE HealthCare Technologies stock logo

45. GE HealthCare Technologies NASDAQ:GEHC

$73.17 -0.23 (-0.31%)
Closing price 08/18/2025 04:00 PM Eastern
Extended Trading
$73.33 +0.16 (+0.23%)
As of 04:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The company recently reported strong quarterly earnings, with earnings per share of $1.06, surpassing analysts' expectations, indicating robust financial performance.
  • GE HealthCare Technologies Inc. has a solid return on equity of 23.93%, suggesting effective management and profitability relative to shareholder equity.
  • The current stock price is around $73.54, which may present a buying opportunity for investors looking for value in the healthcare technology sector.

Cons of GE HealthCare Technologies

  • The stock has experienced volatility, with a 52-week high of $94.80 and a low of $57.65, which may indicate uncertainty in the market.
  • The company's quick ratio is 0.93, suggesting that it may face challenges in meeting short-term liabilities without selling inventory.
  • Recent price target reductions by analysts, including a drop from $94.00 to $82.00, may reflect concerns about future growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.51 billion
P/E Ratio
14.99
Consensus Rating
Moderate Buy
Consensus Price Target
$88.55 (+21.0% Upside)
Volume
2.29 million shares
Average Volume
4.23 million shares
Today's Range
$72.71
$73.78
50-Day Range
$69.85
$77.74
52-Week Range
$57.65
$94.80
Dividend Yield
0.19%
IQVIA stock logo

46. IQVIA NYSE:IQV

$192.58 +1.49 (+0.78%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$188.00 -4.58 (-2.38%)
As of 04:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The current stock price is around $190, which may present a buying opportunity for investors looking for growth in the healthcare analytics sector.
  • IQVIA Holdings Inc. reported a strong earnings performance recently, with earnings per share (EPS) of $2.81, surpassing analysts' expectations, indicating robust financial health.
  • The company has shown a year-over-year revenue increase of 5.3%, suggesting a positive growth trajectory and resilience in its business model.

Cons of IQVIA

  • The company has a relatively high debt-to-equity ratio of 2.45, which may indicate financial risk and reliance on debt for growth.
  • IQVIA Holdings Inc. has a quick ratio of 0.84, suggesting potential liquidity issues, as it may not have enough short-term assets to cover its short-term liabilities.
  • Recent trading volume was significantly lower than its average, which could indicate reduced investor interest or confidence in the stock.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.49 billion
P/E Ratio
27.87
Consensus Rating
Moderate Buy
Consensus Price Target
$228.62 (+18.7% Upside)
Volume
1.34 million shares
Average Volume
2.20 million shares
Today's Range
$190.32
$193.59
50-Day Range
$154.10
$201.06
52-Week Range
$134.65
$252.88
Dividend Yield
N/A
DexCom stock logo

47. DexCom NASDAQ:DXCM

$80.82 -0.13 (-0.16%)
Closing price 08/18/2025 04:00 PM Eastern
Extended Trading
$81.28 +0.46 (+0.57%)
As of 04:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • Recent analyst upgrades have increased target prices, with several firms setting targets around $106.00, indicating strong market confidence in the company's growth potential.
  • The current stock price is approximately $106.00, reflecting a positive trend and investor interest in DexCom, Inc.'s performance.
  • DexCom, Inc. has a robust product line in continuous glucose monitoring systems, which are essential for diabetes management, catering to a growing market of patients and healthcare providers.

Cons of DexCom

  • Despite positive ratings, there are still four analysts who have rated the stock with a hold rating, suggesting some uncertainty about its future performance.
  • Some analysts have lowered their price targets, indicating that there may be concerns about the company's growth trajectory or market conditions.
  • The competitive landscape in the medical device industry is intense, which could impact DexCom, Inc.'s market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.74 billion
P/E Ratio
56.13
Consensus Rating
Moderate Buy
Consensus Price Target
$99.89 (+23.6% Upside)
Volume
2.98 million shares
Average Volume
3.81 million shares
Today's Range
$80.32
$81.74
50-Day Range
$75.46
$89.53
52-Week Range
$57.52
$93.25
Dividend Yield
N/A
BioNTech stock logo

48. BioNTech NASDAQ:BNTX

$112.55 -0.97 (-0.85%)
Closing price 08/18/2025 04:00 PM Eastern
Extended Trading
$113.54 +0.98 (+0.88%)
As of 04:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. More about BioNTech

Pros of BioNTech

  • The current stock price is around $155, reflecting a positive outlook from analysts who have recently upgraded their target prices.
  • BioNTech SE has shown significant revenue growth, with quarterly revenue increasing by over 100% compared to the same period last year, indicating strong demand for its products.
  • Thirteen analysts have given BioNTech SE a buy rating, suggesting strong confidence in the company's future performance.

Cons of BioNTech

  • The company reported a loss of $1.60 per share, which was worse than analysts' expectations, indicating potential challenges in profitability.
  • BioNTech SE has a negative return on equity, suggesting that the company is not currently generating profit relative to shareholder equity.
  • There is a consensus expectation of a negative earnings per share for the current year, which may raise concerns about future profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$27.29 billion
P/E Ratio
-70.34
Consensus Rating
Moderate Buy
Consensus Price Target
$135.80 (+20.7% Upside)
Volume
398,931 shares
Average Volume
688,783 shares
Today's Range
$112.50
$114.15
50-Day Range
$103.01
$115.31
52-Week Range
$81.20
$131.49
Dividend Yield
N/A
Mettler-Toledo International stock logo

49. Mettler-Toledo International NYSE:MTD

$1,315.45 +3.11 (+0.24%)
Closing price 08/18/2025 03:59 PM Eastern
Extended Trading
$1,312.02 -3.44 (-0.26%)
As of 08/18/2025 05:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. More about Mettler-Toledo International

Pros of Mettler-Toledo International

  • The current stock price is around $1,210, which reflects a strong market position and investor confidence in the company's growth potential.
  • Mettler-Toledo International Inc. reported earnings per share (EPS) of $10.09 for the latest quarter, exceeding analyst expectations, indicating robust financial performance.
  • The company has shown a year-over-year revenue increase of 3.9%, suggesting consistent demand for its precision instruments and services.

Cons of Mettler-Toledo International

  • The company has a high price-to-earnings (P/E) ratio of 33.30, which may suggest that the stock is overvalued compared to its earnings.
  • Mettler-Toledo International Inc. has a negative return on equity of 476.07%, indicating potential inefficiencies in generating profit from shareholders' equity.
  • Recent analyst ratings show mixed sentiments, with several firms downgrading their price targets, which could signal caution among investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$27.03 billion
P/E Ratio
33.31
Consensus Rating
Moderate Buy
Consensus Price Target
$1,288.89 (-2.0% Downside)
Volume
127,997 shares
Average Volume
171,442 shares
Today's Range
$1,304.25
$1,330.06
50-Day Range
$1,147.24
$1,324.30
52-Week Range
$946.69
$1,521.01
Dividend Yield
N/A
Insmed stock logo

50. Insmed NASDAQ:INSM

$127.27 -0.53 (-0.41%)
Closing price 08/18/2025 04:00 PM Eastern
Extended Trading
$127.00 -0.27 (-0.22%)
As of 05:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Market Capitalization
$27.01 billion
P/E Ratio
-22.29
Consensus Rating
Moderate Buy
Consensus Price Target
$129.57 (+1.8% Upside)
Volume
3.43 million shares
Average Volume
3.04 million shares
Today's Range
$127.13
$130.13
50-Day Range
$90.93
$127.80
52-Week Range
$60.40
$130.13
Dividend Yield
N/A